SCHEMBL13035700

SCHEMBL13035700

Fc1cccc(Cl)c1C1Nc2cccc3cccc(c23)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 17/20 1.00
KMT2A Q03164 17/20 1.00
GAA P10253 9/20 0.78
L3MBTL1 Q9Y468 2/20 0.78
PBRM1 Q86U86 3/20 0.64
SMARCA2 P51531 2/20 0.64
SMARCA4 P51532 2/20 0.64
POLB P06746 3/20 0.59
NPC1 O15118 2/20 0.53
MCL1 Q07820 2/20 0.50
ALDH1A1 P00352 5/20 0.47
MAPT P10636 5/20 0.47
KDM4E B2RXH2 2/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HPGD P15428 3/20 0.45
ALOX15 P16050 3/20 0.45
ALOX12 P18054 3/20 0.45
HSD17B10 Q99714 2/20 0.45
AR P10275 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14709352 0.88 MEN1 (1.00) MEN1KMT2AGAAL3MBTL1POLB
SCHEMBL24743578 0.78 PBRM1 (1.00) MEN1KMT2AGAAL3MBTL1PBRM1
SCHEMBL24743579 0.78 PBRM1 (0.69) MEN1KMT2AGAAL3MBTL1PBRM1
SCHEMBL24743573 0.77 PBRM1 (1.00) MEN1KMT2AGAAPBRM1SMARCA2
SCHEMBL24743574 0.77 PBRM1 (0.70) MEN1KMT2AGAAL3MBTL1PBRM1
SCHEMBL14709218 0.75 MEN1 (0.65) MEN1KMT2AGAAL3MBTL1PBRM1
SCHEMBL12783883 0.75 MEN1 (1.00) MEN1KMT2AGAAL3MBTL1PBRM1
SCHEMBL14709216 0.73 MEN1 (1.00) MEN1KMT2AGAAL3MBTL1PBRM1
SCHEMBL13035695 0.69 MEN1 (1.00) MEN1KMT2AGAAL3MBTL1POLB
SCHEMBL11568615 0.69 MEN1 (1.00) MEN1KMT2AGAAL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297046-A1 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors DYNAMIS THERAPEUTICS, INC. (US) 2010-11-25 US disclosed
US-20100297046-A1 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors DYNAMIS THERAPEUTICS, INC. (US) 2010-11-25 US disclosed
WO-2007117394-A2 COMPOSITIONS AND METHODS RELATED TO FRUCTOSAMINE-3-KINASE INHIBITORS DYNAMIS THERAPEUTICS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297046-A1 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors FN3K, ROS1, FN3KRP MEN1 4765/4885KMT2A 2677/4885GAA 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.